Results 201 to 210 of about 15,669 (253)

Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen. [PDF]

Alzheimers Res Ther
Valencia-Olvera AC, Marottoli FM, Ratia K, Thatcher GR, Tai LM.   +4 more
europepmc   +1 more source

Analysis of hemorrhagic transformation and intracerebral hemorrhage under combination therapy with alteplase and antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database. [PDF]

PLoS One
Nakai T, Koseki T, Nakao H, Kato K, Takahashi K, Yamada S, Matsumoto S.   +6 more
europepmc   +1 more source

Primary Adrenal Insufficiency Due to Recurrent Unilateral Adrenal Infarction in a Patient With Myelodysplastic Syndrome With Isolated del(5q). [PDF]

AACE Endocrinol Diabetes
Kitayama S, Seki Y, Kato Y, Takano N, Watanabe D, Ichihara A.   +5 more
europepmc   +1 more source

PUNTA AL LLAPIS. Tractament de la claudicació intermitent. Quin paper hi juga el cilostazol? [PDF]

Llobera, À.
core  

Some of the next articles are maybe not open access.

Related searches:

Cilostazol

Drugs & Aging, 1999
Cilostazol is an antiplatelet agent with vasodilating properties that has been used in the treatment of patients with peripheral ischaemia such as intermittent claudication. The drug inhibits platelet aggregation induced by ADP, collagen and arachidonic acid.
E M, Sorkin, A, Markham
  +6 more sources

Cilostazol

American Journal of Health-System Pharmacy, 2002
Cilostazol is a phosphodiesterase III inhibitor that has been shown to be effective for treatment of symptomatic intermittent claudication. It is generally well tolerated, but is contraindicated in patients with severe heart failure because of the potential detrimental effects demonstrated by other agents in the same class.
  +7 more sources

Cilostazol

Reactions Weekly, 2007
Yasuo Ikeda, Toshiki Sudo, Yukio Kimura
  +4 more sources